Literature DB >> 15648779

Morphoproteomic portrait of the mTOR pathway in mesenchymal chondrosarcoma.

Robert E Brown1.   

Abstract

Morphoproteomics is defined as the identification by immunohistochemistry of the molecular circuitry of various proteins in a tumor by noting their state of activation (translocation and phosphorylation) and correlative expressions. Such an approach can uncover or confirm potential molecular targets that may be essential to the growth, integrity, and histogenesis of a particular tumor type and that are amenable to specific therapeutic interventions. This communication illustrates the application of such an approach in depicting the mTOR pathway in mesenchymal chondrosarcoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15648779

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  9 in total

1.  Morphoproteomics: a novel approach to identify potential therapeutic targets in cancer patients.

Authors:  Dongfeng Tan
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

2.  Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.

Authors:  Sadhna Dhingra; Michelle E Rodriguez; Qi Shen; Xuizhen Duan; Melissa L Stanton; Lei Chen; Rongzhen Zhang; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2010-01-28

3.  Patient-derived xenografts and in vitro model show rationale for imatinib mesylate repurposing in HEY1-NCoA2-driven mesenchymal chondrosarcoma.

Authors:  Polona Safaric Tepes; Raffaella Sordella; Danilo Segovia; Sania Jevtic; Daniel Ramirez; Scott K Lyons
Journal:  Lab Invest       Date:  2021-11-26       Impact factor: 5.502

4.  Ezrin immunohistochemical expression in cartilaginous tumours: a useful tool for differential diagnosis between chondroblastic osteosarcoma and chondrosarcoma.

Authors:  Sébastien Salas; Gonzague de Pinieux; Anne Gomez-Brouchet; Frédérique Larrousserie; Xavier Leroy; Sébastien Aubert; Anne-Valérie Decouvelaere; Roch Giorgi; Carla Fernandez; Corinne Bouvier
Journal:  Virchows Arch       Date:  2008-12-03       Impact factor: 4.064

5.  Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.

Authors:  Yvonne de Jong; Annemiek M van Maldegem; Adrian Marino-Enriquez; Danielle de Jong; Johnny Suijker; Inge H Briaire-de Bruijn; Alwine B Kruisselbrink; Anne-Marie Cleton-Jansen; Karoly Szuhai; Hans Gelderblom; Jonathan A Fletcher; Judith V M G Bovée
Journal:  Lab Invest       Date:  2016-09-12       Impact factor: 5.662

Review 6.  Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology.

Authors:  Marc El Beaino; Jason Roszik; John A Livingston; Wei-Lien Wang; Alexander J Lazar; Behrang Amini; Vivek Subbiah; Valerae Lewis; Anthony P Conley
Journal:  Curr Oncol Rep       Date:  2018-03-26       Impact factor: 5.075

7.  miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas.

Authors:  Angélique Gougelet; Jennifer Perez; Daniel Pissaloux; Anthony Besse; Adeline Duc; Anne-Valérie Decouvelaere; Dominique Ranchere-Vince; Jean-Yves Blay; Laurent Alberti
Journal:  Sarcoma       Date:  2011-02-22

8.  The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets.

Authors:  E David; F Blanchard; M F Heymann; G De Pinieux; F Gouin; F Rédini; D Heymann
Journal:  Sarcoma       Date:  2011-05-22

9.  Genomic profiling identifies genes and pathways dysregulated by HEY1-NCOA2 fusion and shines a light on mesenchymal chondrosarcoma tumorigenesis.

Authors:  Wenqing Qi; Wojciech Rosikiewicz; Zhaohong Yin; Beisi Xu; Huihong Jiang; Shibiao Wan; Yiping Fan; Gang Wu; Lu Wang
Journal:  J Pathol       Date:  2022-04-26       Impact factor: 9.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.